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Glutamate transporters, located in plasma membranes of
nerve and glial cells, are instrumental in keeping the synaptic
concentration of the transmitter below neurotoxic levels (1– 4).
Moreover, together with diffusion, they may help to terminate
its action in synaptic transmission (5, 6). They achieve this by
an electrogenic process (7–9) where the transmitter is cotransported with three sodium ions and a proton (10), followed by
countertransport of a potassium ion (10 –13).
A glutamate transporter has been purified to near homogeneity and reconstituted (14, 15). This transporter, termed
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GLT-1, has been cloned (16), and its physiological importance is
illustrated in knock-out experiments (3, 4). Four other glutamate isotransporters have been cloned (17–20) and the homology between these family members is around 50%.
Recently we identified two residues of GLT-1 important for
potassium coupling (13, 21). These residues, tyrosine 403 and
glutamate 404, are located in the most conserved region of the
transporter. Nearby in the primary sequence is aspartate 398,
which is also critical for transporter function (22). These and
other observations, suggest that this region may form part of
the translocation pathway of the transporter. The scanning
cysteine accessibility method (SCAM1) has permitted the systematic identification of residues lining ion channels (for instance, 23–25). We have therefore used this method to probe
the accessibility of residues 395– 407. Strikingly, this study has
led to the identification of a conformationally sensitive residue.
We suggest that it is alternatingly accessible from either side of
the membrane in a substrate-dependent manner.
EXPERIMENTAL PROCEDURES

Cell Growth and Expression—HeLa cells were cultured (26), infected
with recombinant vaccinia/T7 virus vTF7–3 (27), and transfected with
plasmid DNA encoding wild type or mutant GLT-1 (26). Transport
experiments with the GLT-1 substrate D-[3H]aspartate were done as
described (22). Data presented are after subtracting the values obtained
from cells transfected with the vector, pBluescript SK2, alone. In the
case of some of the mutants and in particular if they were subcloned
into the cDNA encoding the cysteine-less GLT-1 (see below), the sodium
concentration of the transport medium was lowered to 15 mM (supplemented with 135 mM choline chloride) as the sodium affinity of aspartate transport endogenous to the HeLa cells is much lower than that of
GLT-1 and its derivatives (data not shown). This enables us to obtain
acceptable signal/background ratios, at least 4-fold, even in the case of
relatively low activities exhibited by the cysteine-less transporter and
its derivatives.
Inhibition Studies with Sulfhydryl Reagents—Prior to the transport
measurements, the cells, adhered to 24-well plates, were washed with
the 150 mM NaCl containing transport medium. Each well was then
incubated at room temperature with 200 m l of this solution (in case of
different composition this is indicated in the figure legends) and the
indicated concentration of reagent under study. After 5 min the medium
was aspirated, and the cells were washed twice with 1 ml of the
transport solution. Subsequently they were assayed for D-[3H]aspartate
transport using solution to which the labeled amino acid was added
(22). The hydrophilic methanethiosulfonate (MTS) reagents used were
purchased from Toronto Research Chemicals, Inc. Positively charged
MTSEA and MTSET are approximately 1 nm in length, differing only at
the charged head group, which measures 0.58 nm in MTSET and 0.36
nm in MTSEA (23). MTSES is negatively charged and has an intermediate size (23). Whereas MTSEA is membrane permeant to some extent,

1
The abbreviations used are: SCAM, scanning cysteine accessibility
method; MTS, methanethiosulfonate; MTSEA, (2-aminoethyl)methanethiosulfonate; MTSET, (2-(trimethylammonium)ethyl)methanethiosulfonate; MTSES, (2-sulfonatoethyl)methanethiosulfonate; NEM,
N-ethylmaleimide.
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Glutamate transporters remove this transmitter from
the extracellular space by cotransport with three sodium ions and a proton. The cycle is completed by translocation of a potassium ion in the opposite direction.
Recently we have identified two adjacent amino acid
residues of the glutamate transporter GLT-1 that influence potassium coupling. Using the scanning cysteine
accessibility method we have now explored the highly
conserved region surrounding them. Replacement of
each of the five consecutive residues 396 – 400 by cysteine abolished transport activity but at several other
positions the substitution is tolerated. One residue, tyrosine 403, was identified where cysteine substitution
renders the transporter sensitive to modification by
positively charged methanethiosulfonate derivates in a
sodium-protectable fashion. In the presence of sodium,
the nontransported glutamate analogue dihydrokainate
potentiated the covalent modification, presumably by
binding to the glutamate site and locking the protein in
a conformation in which tyrosine 403 is accessible from
the external bulk medium. In contrast, transported substrates significantly slowed the reaction, suggesting that
during the transport cycle residue 403 becomes occluded.
On the other hand, transportable substrates are not able
to protect Y403C transporters against N-ethylmaleimide,
which is highly permeant but unable to modify cysteine
residues buried within membrane proteins. These results
indicate that tyrosine 403 is alternately accessible from
either side of the membrane, consistent with its role as
structural determinant of the potassium binding site.
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the other two compounds are impermeant (28).
Site-directed Mutagenesis—Mutagenesis (22, 29) was done using
uracil-containing single strand DNA derived from the shortened GLT-1
clone (30) or its cysteine-less homologue. Most results reported in this
study concern individual replacements of selected residues of the wild
type GLT-1 by cysteine, but cysteine mutants in a cysteine-less background were also tested to confirm the specificity of the effects observed
in the wild type background. The cysteine-less GLT-1 was prepared and
characterized as follows: Cysteines 536, 549 and 562 are clustered
together at the carboxyl-terminal tail. Because we have evidence that
the major part of this tail is not required for transport,2 the stretch from
residue 533 to residue 563 was deleted by site-directed mutagenesis. At
the same cycle of the mutagenesis another primer was annealed simultaneously to the uracil-containing single-stranded DNA. It was designed to convert cysteine 38 to serine. After verifying by DNA sequencing that these changes were indeed incorporated, the construct was
expressed and shown to be unimpaired for D-[3H]aspartate transport.
Subsequently uracil-containing single-stranded DNA was prepared
from this construct, and new cycles of mutagenesis, sequencing, and
expression were performed to mutate the remaining cysteines to serine.
In the second cycle, cysteines 60, 293, and 296 were converted, in the
third 184, and in the fourth 373. In the subsequent cycle a decahistidine tail was introduced between the last residue of GLT-1, lysine
573, and the stop codon. A major reason to prepare the above construct
was for the determination of the membrane topology of GLT-1 by one of
2

G. Pines and B. I. Kanner, unpublished observations.

several approaches,3 namely, biotinylation of single cysteine-containing
transporters. In this approach artifactual biotinylated bands are observed running with a similar mobility as the above described construct. To detect transporter-related signals, it was necessary to “masstag” the construct so that the transporter band would be resolved from
the artifactual ones. We have shown previously that most of the aminoterminal tail of the GABA transporter GAT-1 is not required for its
functional expression (31). Therefore, we have inserted upstream of the
original first methionine the coding sequence for the first 41 amino
acids of GAT-1 preceded by the DNA sequence 59-ATGCATTTCGTGCTCCGAGAC-39, encoding for the amino acids MHFVLRD; the latter
was added to facilitate its insertion using standard molecular biology
approaches. Using GAT-1 as a template, the primers used for amplification were designed such that on both ends of the amplified fragment
a StuI site was created. After digestion with StuI, the fragment was
ligated into blunt ends created in the cysteine-less histidine-tagged
GLT-1 described above, by cutting it with PflMI and removal of the
39-overhangs with bacteriophage T4 DNA polymerase. Plasmid DNA of
several of the transformants was isolated and one of those, which gave
rise to aspartate transport after expression, was retained. The result is
that the 48 amino acids are inserted immediately amino-terminal to the
original start codon of GLT-1. All the expected features of the modified
cysteine-less GLT-1 were verified by sequencing in both directions and
upon expression its D-[3H]aspartate transport activity was found to be
3
M. Grunewald, A. Bendahan, and B. I. Kanner, submitted for
publication.
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FIG. 1. Characteristics of D-[3H]aspartate uptake by the cysteine-less
GLT-1. HeLa cells were infected with the
recombinant vaccinia/T7 virus and transfected with cDNA of the wild type or the
cysteine-less GLT-1. After washing the
cells with 150 mM choline chloride medium transport of D-[3H]aspartate was
measured as described under “Experimental Procedures.” The influx solutions
were supplemented with the indicated
concentrations of unlabeled D-aspartate
(A). In B the 150 mM NaCl medium was
used as the 100% value, and the sodium
concentration was varied as indicated using choline chloride to supplement the
chloride salt concentration to 150 mM.
Values are the average (6 S.E.) of triplicate determinations and are expressed as
percent activity of wild type or cysteineless GLT-1 measured in the presence of
150 mM NaCl in the absence of unlabeled
D-aspartate. f, GLT-1; ●, cysteine-less
GLT-1.
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FIG. 2. Sodium-dependent D-[3H]aspartate uptake in HeLa cells expressing wild type and mutant transporters. Uptake was measured as described
under “Experimental Procedures.” Values
are average (6 S.E.)of triplicate determinations and are expressed as percent of
wild type values.

44.5 6 1.5% of that of the wild type GLT-1 (n 5 7), and the level of
expression as estimated by immunoprecipitation was comparable to
that of the wild type (data not shown). The characteristics of transport
of this cysteine-less histidine-tagged GLT-1 transporter were very similar to that of the wild type GLT-1, as judged by affinity to D-aspartate
(Fig. 1A) and sodium (Fig. 1B). Single cysteine-containing transporters
were made using uracil-containing single strand DNA derived from this
construct. Mutants were verified by DNA sequencing. Mutations Y403C
and E404C were subcloned into wild type or cysteine-less GLT-1 using
the enzymes BsrGI and BstEII. Subcloned DNAs were sequenced in
both directions between these restriction sites.
RESULTS

Cysteine-scanning Accessibility of Residues 395– 407—Residues 395– 407 of the glutamate transporter GLT-1 have been
changed one at a time to cysteine. After transient expression of
the wild type and the cysteine replacement mutants in HeLa
cells, transport of D-[3H]aspartate was monitored.
No transport can be detected when cysteine is introduced in
each of the five consecutive residues from 396 to 400 (Fig. 2).
The possible role of these residues in the transport process will
be addressed under “Discussion.” Right now we focus on the
remaining residues, where cysteine replacement leaves significant biological activity (Fig. 2).
Transport activity of wild type GLT-1 is not inhibited by 2.5

mM of the MTS derivative (MTSEA), and the same is true for all
the active cysteine replacement mutants with the exception of
Y403C (Fig. 3). When the preincubation with the sulfhydryl
reagent is carried out in a sodium-free medium (choline substitution) E404C transporters become sensitive to the reagent
as well (Fig. 4). It appears that sodium protects against covalent modification at this position, since similar data are obtained when the E404C mutation is introduced in a cysteineless GLT-1 background (data not shown). Although not visible
in the experiments depicted in Figs. 3 and 4, there is also a
partial protection of Y403C transporters by sodium against
inhibition by MTSEA. This can be readily observed at lower
concentrations of this sulfhydryl reagent (Fig. 5). Similar results have been observed with the Y403C mutation introduced
in a cysteine-less background (data not shown, but see Fig. 9).
Other cations are not effective except for lithium, which affords
a small but significant protection (data not shown). It is of
interest to note that also in the case of E404C, lithium is the
only cation besides sodium that can give a significant protection against inhibition by MTSEA (data not shown).
Characterization of the Inhibition of Y403C by MTS Reagents—As will be shown below, the most striking observation
described in this paper is the opposite effect of transportable
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FIG. 3. Inhibition of transport by
MTSEA in the presence of sodium.
HeLa cells, expressing wild type or the
indicated mutant transporters, were
washed with the standard NaCl medium
and subsequently preincubated in the
same medium supplemented with 2.5 mM
MTSEA. After 5 min at room temperature
the cells were washed and assayed for
3
D-[ H]aspartate transport as described
under “Experimental Procedures.”
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FIG. 4. Inhibition of transport by
MTSEA in the absence of sodium.
This was carried out exactly as described
in the legend to Fig. 3, except that in the
preincubation and washing solutions sodium was replaced by the same concentration of choline.

and nontransportable substrates on the inhibition of Y403C by
MTS reagents in a sodium-containing medium. In contrast,
E404C transporters are not inhibited very much by MTSEA in
the presence of sodium (Fig. 3), and the same is true when
transporter substrates are added (data not shown). Therefore,
we have focused on the characterization of functional effects of
covalent modification of Y403C transporters. Wild type GLT-1
is not inhibited by the positively charged MTSEA and MTSET
(Figs. 3, 4, and 6A) and also not by MTSES (data not shown). In
contrast with wild type, not only MTSEA (Fig. 3) but also
MTSET potently inhibit Y403C transporters (Fig. 6A). On the
other hand, negatively charged MTSES does not (Fig. 6B).
Because MTSES is intermediate in size between MTSEA and
MTSET (23), it appears that the positive charge in the reagent
determines its ability to inhibit. After preincubation of Y403C
transporters with MTSES, they still can be inhibited by a
subsequent exposure to MTSEA (Fig. 6B). This speaks against
the possibility that the residue can be covalently modified
MTSES but that this does not lead to inhibition of transport.
In the experiment depicted in Fig. 7, Y403C transporters are
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FIG. 5. Effect of sodium on inhibition of the Y403C transporter
by MTSEA. HeLa cells expressing the transporters were preincubated
for 5 min in sodium- or choline chloride-containing media without
(control) or with 0.25 mM MTSEA. After washing the cells, sodium-dependent uptake of D-[3H]aspartate was measured in triplicate in a 15
mM NaCl 1 135 mM choline chloride-containing medium. Data are
presented as percent activity of the control (6 S.E.) of each condition.

preincubated with 0.25 mM MTSEA in a sodium-containing
medium. When transport of D-[3H]aspartate is subsequently
measured, an inhibition of almost 80% is observed. When a
saturating concentration (1 mM) of transportable acidic amino
acids such as D- and L-aspartate or L-glutamate is added during
the preincubation, this causes a marked protection of the transporters against the inhibition by MTSEA (Fig. 7). This protection is only observed in the presence of sodium ions (data not
shown). Amino acids that are not substrates of GLT-1, such as
GABA or glycine, do not protect (Fig. 7). The protective effect of
D-aspartate is dose dependent; half-maximal effects are observed with 30 –50 mM (data not shown), which is in good
agreement with the apparent Km of D-aspartate transport in
HeLa cells expressing GLT-1 (22). The protection by D-aspartate is observed at all MTSEA concentrations examined (Fig.
8A). The substrate similarly affords protection against the impermeant MTSET (Fig. 8B). It is also apparent that the larger
MTSET inhibits less potently than MTSEA, presumably because of steric constraints. Again, inhibition by the MTS reagents and the protection by transportable substrates are the
consequence of a direct modification of the cysteine at the 403
position, because similar results are obtained with transporters in which this is the only cysteine (Fig. 9). Strikingly, the
competitive inhibitor dihydrokainate (12, 32), a nontransportable glutamate analogue (32–34), does not protect, and in fact
even potentiates the inhibition by the MTS reagents. Thus
transportable substrates induce a conformational change making the residue less accessible to the impermeant reagent,
whereas the blocker seems to lock the transporter in a conformation where it is more accessible to the extracellular bulk
medium. Importantly, the wild type as well as the cysteine-less
GLT-1 are not inhibited by MTSEA and MTSET even in the
simultaneous presence of dihydrokainate (data not shown).
Effects of NEM—The conformational change induced by aspartate may cause burial of the 403 residue within the core of
the transporter. Alternatively, it may reflect the transport step
itself, and the residue may become accessible to the inside bulk
medium. In the former case the residue is not expected to be
reachable by NEM, which permeates lipid bilayers readily but
is unable to modify cysteine residues within transmembranespanning a helices (35, 36). The maleimide does not inhibit wild
type GLT-1 (data not shown) but inhibits the activity of the
Y403C transporter (Fig. 10). In contrast with its protection
against MTS reagents, D-aspartate does not protect the Y403C
transporters against NEM (Fig. 10). This is consistent with the
idea that its protection against relatively impermeant MTS
reagents is because of the movement of the 403 residue from
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FIG. 7. Effect of amino acids on inhibition of Y403C transporters by
MTSEA. HeLa cells expressing Y403C
were incubated in the standard medium
in the presence and absence of 0.25 mM
MTSEA ( ) and the indicated amino acids (at 1 mM final concentrations). After
washing, transport in the low sodium medium was measured, and the data are
expressed as percent activity remaining
relative to the respective control without
MTSEA. f, control.

the outside of the cell to the inside. Similar results are obtained
with the mutation introduced in a cysteine-less background
(data not shown). The partial protection observed with dihydrokainate will be discussed below.
DISCUSSION

Analysis of amino acid residues 395– 407 of GLT-1 by SCAM
leads to two major conclusions: 1) Within the putative poreforming domain of GLT-1 are five consecutive residues (396 –
400) where mutation to cysteine leads to complete loss of function, a result consistent with the structural conservation and
functional importance of this region. 2) Residue 403, which has
been previously shown to interact with cotransported cations
(21), behaves as if it is alternately accessible from either side of
the membrane in such a way that glutamate transport promotes

its exposure to the inside, whereas binding of a nontransportable
analog promotes its exposure to the outside. This residue is
located in the middle of transmembrane a-helix seven (37).3
One of the five residues that do not tolerate replacement by
cysteine (Fig. 2) is aspartate 398. Its replacement by either
asparagine, glycine, or glutamate also leads to loss of function,
and this is not because of a defective biosynthesis or targeting
(22). Injection of D398E cRNA into Xenopus oocytes results in
neither glutamate transport currents nor transient currents
reflecting sodium binding.4 It is possible therefore that this
residue, together with asparagine 396, methionine 397, glycine

4
J. I. Wadiche, B. I. Kanner, and M. P. Kavanaugh, unpublished
experiments.
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FIG. 6. Effect of other MTS reagents
on Y403C transporters. HeLa cells expressing wild type or Y403C transporters
were preincubated in the standard NaCl
medium containing 2.5 mM MTSEA ( ) or
1 mM MTSET ( ) (A) or 10 mM MTSES (B)
for 5 min. In B an additional 5 min of
incubation with 2.5 mM MTSEA was carried out. Subsequently transport was
measured using the 15 mM NaCl 1 135
mM choline chloride-containing medium.
f, control; WT, wild type.
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the idea that it is part of a negatively charged binding pocket
for cations, which repels the negatively charged MTSES.
On the other hand, the protection by transportable acidic
amino acids against inhibition by positively charged MTS reagents (Figs. 7–9) is because of a conformational change induced by their binding at a distinct site. This is inferred because the opposite effect is induced by binding to this site of the
nontransportable dihydrokainate, which locks the transporter
in a conformation where tyrosine 403 is accessible from the
external bulk medium. Transportable substrates cause a conformational change where this residue becomes occluded. Further evidence for a close association of this phenomenon with
the transport step itself is that it was only observed in the
presence of the cosubstrate sodium. The sensitivity to NEM
during transport conditions (Fig. 10), in contrast to the protection against MTS reagents (Figs. 8 and 9), suggests that now
tyrosine 403 becomes accessible to the aqueous intracellular
compartment.
Determinants of the binding site for the acidic amino acids
are located on a stretch of 76 amino acid residues (39), which
also contains the cation binding site (13, 21). One explanation
for the partial protection by dihydrokainate against NEM may

FIG. 8. Effect of D-aspartate and dihydrokainic acid on inhibition of transport of Y403C by MTSEA and MTSET. Cells expressing Y403C transporters were preincubated under standard conditions
with the indicated concentrations of MTSEA or MTSET in the absence
(f) or presence of 1 mM of either dihydrokainate (Œ) or D-aspartate (●).
Uptake was measured in the low sodium-containing medium.

FIG. 10. Effect of D-aspartate and dihydrokainic acid on the
inhibition of transport of Y403C by N-ethylmaleimide. HeLa cells
expressing Y403C were incubated with the indicated concentrations of
N-ethylmaleimide (NEM) in the presence or absence of 1 mM of either
D-aspartate or dihydrokainic acid. Transport was done in the low sodium-containing medium. Con, control; dAsp, D-aspartate; DHK, dihydrokainic acid.

FIG. 9. Effect of D-aspartate and dihydrokainic acid on inhibition of
transport of Y403C in a cysteine-less
background. The conditions were as described in the legend to Fig. 8 using MTSEA at 0.1 mM. It should be noted that
here, in contrast, to Fig. 8, data are presented as % inhibition.
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399, and threonine 400, plays a crucial role in sodium binding.
Recent experiments in our laboratory indicate that sodium and
potassium binding sites are close to each other (21). Glutamate
404 and tyrosine 403 are involved in potassium binding (13,
21), and residues 396 – 400 are in fact nearby. Consistent with
this is the protection of E404C and Y403C transporters by
sodium against thiol modification (Figs. 3–5). This modification
occurs at these very positions, as evidenced by the fact that the
same results are also obtained in a cysteine-less background.
This rules out a scenario in which the introduction of a new
cysteine residue induces a change in the transporter’s structure such that modification now may occur at one of the nine
endogenous cysteines of GLT-1. The cysteine-less GLT-1 transporter has around 40% of the wild type activity, and therefore
most of the experiments have been done in the wild type background. However, they have been validated in the cysteine-less
background as shown, for instance, in Fig. 9. It is of interest to
note that the only ion that can partially substitute for sodium
in the protection experiments is lithium. This is not unexpected
as only this cation can replace some of the three sodium ions in
the transport process (38). The fact that only positively charged
MTS reagents inhibit at the 403 position (Fig. 6), also supports
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be that the former is bound close enough to hamper the access
of NEM, which is bulkier than the MTS reagents.
Tyrosine 403 is involved in the interaction of the transporter
with internal as well as external potassium (21) and it appears,
together with glutamate 404 (13), to be a structural determinant of the potassium site. Because of the role of potassium,
which is to promote the return of the unloaded transporter to
the side of the membrane from where substrate can be moved
(11–13), it is to be anticipated that during the transport cycle
the potassium binding site should be alternately accessible to
either side of the membrane. The findings documented here are
entirely consistent with this. We anticipate that application of
SCAM to other interesting regions of GLT-1 and to other transporters, may lead to important structural and functional insights as well.
Acknowledgments—We thank Beryl Levene for expert secretarial
assistance.
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